OTC F-Stocks Holiday Momentum Watchlist (TBRIF, PYRGF, NYMXF, MGDPF)

One technique many investors use to book profits is to find stocks that are gaining momentum. These stocks that make big moves can stay in an uptrend for multiple trading sessions, providing savvy investors with potential gains.

Investors are always looking for catalysts that may impact price moves. One big driver that often impacts prices is news. Positive news sometimes has the ability to send stocks soaring.

Let’s take a closer look at four F-listed stocks with momentum that might deserve a spot on your watchlist

Therma Bright Inc. (OTCQB: TBRIF) (TSXV: THRM) is a pioneering force in the realm of diagnostic and medical device technologies, dedicated to addressing prevalent medical challenges.

The company recently marked a significant development by opening existing and new distribution channels for its Venowave device. Multiple channel partners have expressed keen interest in evaluating the commercial viability of the Venowave device following successful pilot tests and doctor-patient validation. The pilot units have been promptly dispatched for distribution, with CEO Rob Fia expressing optimism about potential commercial volumes upon successful pilot tests.

In a parallel stride, Therma Bright is actively collaborating with the U.S. Food and Drug Administration (FDA) on an updated 510K application for the Venowave device. This application corrects the device’s intended use, labeling, and product description, aligning it more effectively with the U.S. Centers for Medicare and Medicaid Services (CMS) application for permanent Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding System (HCPCS) codes.

Another noteworthy advancement came in November when Therma Bright prepared an FDA 513(g) Review Document for its AI-Driven Digital Cough Analyzer (DCA). Developed in collaboration with AI4LYF, this innovative solution offers a robust set of features for both users and medical practitioners. The DCA mobile app, available on Android and iOS, incorporates AI-based cough detection, continuous cough counting, and user controls for data management and sharing. On the clinician dashboard, healthcare professionals can review patient cough data in a HIPAA-compliant manner, enhancing remote therapeutic monitoring.

CEO Rob Fia highlighted the unique features of the Digital Cough Analyzer, emphasizing its potential to support healthcare providers and patients alike. The acoustic AI-driven technology not only offers privacy-preserving cough detection but also opens avenues for data-driven research on various health issues. The potential for distinguishing between different cough signatures, such as those related to flu, COVID-19, or lung cancer, positions Therma Bright as a key player in advancing healthcare through innovative technologies.

Furthermore, Therma Bright’s recent tweet from @bright_therma indicates that the executive team is finalizing the year-end financial statements, MD&A, and supporting documents, showcasing progress on key business initiatives and partnerships, including Venowave and DCA.

In conclusion, Therma Bright, Inc. stands at the forefront of innovation in diagnostic and medical device technologies. The recent expansion of distribution channels for the Venowave device, the development of the AI-Driven Digital Cough Analyzer, and ongoing progress on key business initiatives position Therma Bright as a key player in the dynamic landscape of medical technology.

PyroGenesis Canada Inc. (OTCQX: PYRGF) demonstrated impressive trading, rising 12% on December 27. As a key player in advanced plasma processes, PyroGenesis is a leader in designing sustainable solutions that reduce greenhouse gases (GHG) and offer alternatives to conventional processes. The company’s proprietary plasma technologies have gained traction in major markets, including iron ore pelletization, aluminum, waste management, and additive manufacturing.

In a recent milestone, PyroGenesis received a second payment of approximately $520,000 associated with the engineering phase of a plasma torch contract with a U.S. corporation aimed at destroying Perfluoroalkyl and Polyfluoroalkyl substances (PFAS). This innovative plasma torch technology, nearing completion, is set to advance PFAS eradication, addressing critical environmental challenges.

Furthermore, PyroGenesis secured a new U.S. patent for its NexGen plasma atomization technology, a groundbreaking method for producing high-purity spherical metallic powders at high production rates. This patent highlights the efficiency of the NexGen system, offering higher production rates, a narrower particle size distribution, and customization options for customers. The technology’s potential for producing titanium metal powders suitable for various applications positions PyroGenesis as a leader in the additive manufacturing industry.

Mr. Pierre Carabin, PyroGenesis Chief Technology Officer, emphasized the significance of NexGen, stating, “For our customers, that means they receive the finest, most spherically consistent, and densest powders from typical plasma atomization, but with the added benefits of buying from a North American-based source.” The company’s commitment to advancing plasma atomization and its successful commercialization of titanium metal powders contribute to its strategic position in the global heavy industry.

In conclusion, PyroGenesis Canada Inc. continues to make strides in sustainable solutions and innovative technologies. The recent stock performance reflects the market’s recognition of the company’s achievements, and with ongoing developments, PyroGenesis is poised for further success in the dynamic landscape of advanced plasma processes and additive manufacturing.

Nymox Pharmaceutical Corporation (OTC: NYMXF) is making waves in the healthcare sector, with its stock surging an impressive 28.99% as of 2:38 p.m. This boost in value is a testament to the company’s strategic advancements and promising developments in the field of prostate health.

At the forefront of Nymox’s initiatives is the pursuit of regulatory approval for its groundbreaking drug, NYMOZARFEX, designed to treat the symptoms of benign prostatic hyperplasia (BPH). This condition, prevalent among middle-aged and elderly men globally, often comes with debilitating symptoms. Nymox is addressing the limitations of current treatments, which are known for their side effects.

What sets NYMOZARFEX apart is its innovative approach, administered in a quick in-office procedure without the need for anesthesia. With over 1750 patients involved in clinical trials and more than 1600 injections administered, NYNYMOZARFEX has demonstrated significant and lasting improvements. Importantly, it boasts a commendable safety profile, avoiding the typical side effects seen with existing BPH treatments.

Nymox recently shared pivotal 10-year follow-up data from its U.S. clinical trial on NYMOZARFEX, specifically targeting low-grade localized prostate cancer. The long-term data underscored the drug’s substantial and statistically significant benefits in reducing the progression of these cancers.

Looking ahead to 2024, Nymox anticipates a busy year, building on the momentum of its recent achievements. CEO Dr. Paul Averback emphasizes the company’s focus on obtaining approvals for Nymozarfex, recognizing the transformative potential of this novel drug in addressing critical medical needs.

Beyond BPH, Nymox has a second major indication for low-grade prostate cancer, aiming to provide a safe and effective initial treatment option. Prostate cancer, the most common non-skin cancer in men, affects approximately 1 in 8 men. Nymox’s efforts in this area represent a significant step forward in enhancing treatment options for patients.

In summary, Nymox Pharmaceutical Corporation’s stock surge reflects not only its immediate market success but also the promising trajectory of its groundbreaking drug developments. As the company continues to navigate the regulatory landscape, investors and stakeholders are eager to witness the potential positive impact of NYMOZARFEX on revolutionizing prostate health treatments.

Marathon Gold Corporation (OTC: MGDPF) (TSX: MOZ), a Toronto-based gold company, is making significant strides in advancing its 100%-owned Valentine Gold Project, situated in the central region of Newfoundland and Labrador, a renowned mining jurisdiction. The project encompasses five mineralized deposits along a 32-kilometer system, with an updated feasibility study from December 2022 projecting an open-pit mining and conventional milling operation producing 195,000 ounces of gold annually for 12 years.

In recent updates, Marathon achieved a remarkable milestone, completing 1 million person-hours of work at the Valentine Gold Project without a lost time injury (LTI). This accomplishment underscores the company’s commitment to maintaining a safe workplace during the project’s construction phase.

As of the end of the third quarter of 2023, the overall completion of the Valentine Gold Project reached 50%, with a focus on various activities such as erecting structural steel at the grinding building and ongoing construction of the Tailings Management Facility. Importantly, waste rock mining from the Leprechaun Pit is supporting these construction activities.

Furthermore, Marathon Gold announced its intention to merge with Calibre Mining Corp., with Marathon Shareholders (excluding Calibre) receiving 0.6164 of a Calibre common share for each Marathon Share held. The proposed combination aims to create a high-margin, cash-flow-focused, mid-tier gold producer in the Americas with enhanced production growth and improved balance sheets and cash flow. The transaction is expected to close by the end of January 2024, subject to shareholder and court approvals.

The board of directors of Marathon unanimously recommends voting in favor of the proposed combination with Calibre, citing benefits such as a premium for Marathon shareholders, increased scale, an improved balance sheet, the removal of financing risk, significant combined mineral endowment, asset diversification, and continued participation in the Valentine Gold Project.

The Marathon-Cablibre merger represents a strategic move towards creating a robust and diversified gold production company, aligning with Marathon’s goal of delivering value to its shareholders.

Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by TBRIF to assist in the production and distribution of content. ‘CGR’ is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.